DB05616InvestigationalSmall molecule
CH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced... It has been investigated for the treatment of Rheumatoid Arthritis (phase II).
- Mechanism
- Curator reviewed
Pharmacologically active on Thymidylate synthase and Dihydrofolate reductase
- Primary indication
- Investigated for use/treatment in inflammatory disorders (unspecified), psoriasis and psoriatic disorders, and rheumatoid arthritis.Curator reviewed
- Formula / weight
- C23H23N5O5 · 449.467 g/mol (avg)
- Code names
- CH-1504
Resolves to
Compound
Structure
InChIKey
NAWXUBYGYWOOIX-UHFFFAOYSA-NSMILESNC1=NC2=CC=C(CCC3=CC=C(C=C3)C(=O)NC(CC(=C)C(O)=O)C(O)=O)C=C2C(N)=N1Targets
Transporters
What you can answer from here — as of July 03, 2026
2Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
1TransporterSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with 4'-Methylene-5,8,10-trideazaaminopterin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account